Novo bets big on diabetes meds

Share this article:

Novo Nordisk is investing $3.65 billion in needle-free diabetes treatments. Reuters reports that the drug maker is looking to develop pills that can replace injected insulins, and tells the news service it has dedicated 500 employees to developing six candidates.

The company projects that it could have the new medication market-ready in 10 years.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions